Clinical Trial Results Home


Factor XA Inhibition
Factor IX Inhibition

Heparin-Induced Thrombocytopenia

      -Heparin as a Cause of Thrombosis and "The HIT Syndromes" by Dr. Amjad AlMahameed

Hypercoaguable States

      -What Every Clinician Needs to Know by Dr. Amjad AlMahameed

Pathways in Anticoagulation: What's Most Efficacious, Safest

      -Overview by Dr. Richard C. Becker (AHA 2010)

(Return to Contents)

 Factor XA Inhibition

FUTURA OASIS 8: Low vs. Standard Dose Unfractionated Heparin for PCI in ACS Patients Treated with Fondaparinux

      -Trial Results by Dr. Sanjit Jolly (ESC 2010)


New Approaches to Chronic Anticoagulation: Factor XA Inhibition

      -Meeting the Unmet Needs in Chronic Anticoagulation by Dr. C. Michael Gibson (ACC 2007)

XA Inhibitors

      -Are They All the Same? by Dr. Alexander G. G. Turpie

(Return to Contents)

 Factor IX Inhibition

Aptamer Technology Overview:

      -Factor IXa Inhibition Aptamer Technology Overview and First Results with RB006/RB007 by Dr. Mauricio G. Cohen (TCT 2009)


RADAR: A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Weight Heparin in Subjects with Acute Coronary Syndromes

      -Primary Results by Dr. Tom Povsic (ACC 2011)


A Prospective RADAR Pharamacokinetic and Pharmacodynamic Substudy: Pegnivacogin (RB006), a Direct Factor IXa Inhibitor, Results in Consistent and Near Complete Inhibition of Factor IX Activity in Patients with Acute Coronary Syndromes

      -Study Overview by Dr. Thomas Povsic (AHA 2010)

(Return to Contents)


ARISTOTLE: Apixaban versus Warfarin in Patients with Atrial Fibrillation

      -Trial Results by Dr. Christopher Granger and Dr. Lars Wallentin (ESC 2011)

      -Efficacy and Safety by Dr. Christopher Granger and Dr. Lars Wallentin (ESC 2011)


ARISTOTLE Sub-analysis in Japanese patients: Apixaban versus Warfarin in Patients with Atrial Fibrillation

      -Study Overview by Dr. Shinya Goto (ACC 2012)


ARISTOTLE CHADS Subgroup Study: Efficacy and Safety of Apixaban Compared with Warfarin According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation

      -Study Overview by Dr. Renato Lopes (ACC 2012) 


GRACE Registry: Global Registry of Acute Coronary Events

      -Combining Warfarin and Antiplatelet Therapy After Coronary Stenting: Is It Safe and Effective to Use Just One Antiplatelet Agent? by Dr. Michael C. Nguyen


PROTECT AF: Percutaneous Closure of the Left Atrial Appendage versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomized Non-Inferiority Trial

      -Trial Overview by Dr. David R. Holmes (AHA 2002)

RELY: Randomized Evaluation of Long-term anticoagulant therapY

      -Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at Risk of Stroke

      -Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation: Japanese Population by Dr. Shinya Goto


RELY CHADS-VASC2 Subgroup: Randomized Evaluation of Long-term anticoagulant therapY

      -Insights to RELY Subgroup Analysis by Dr. Hisao Ogawa


ROCKET-AF: Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation

   -Trial Overview by Dr. Kenneth Mahaffey and Dr. Keith Fox (AHA 2010)

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at For further information please see the Policy section. Webmaster